Core Viewpoint - Recent activities involving shareholders of Lattice Technology (06809) indicate significant investment interest, with notable stock deposits and purchases reflecting confidence in the company's future performance [1] Group 1: Shareholder Activities - On February 13, Lattice Technology's shareholders deposited stocks into Huatai Hong Kong, with a market value of HKD 1.802 billion, representing 13.04% of the total shares [1] - On February 10, JPMorgan increased its stake in Lattice Technology by acquiring 1.13246 million shares at a price of HKD 177.6932 per share, totaling approximately HKD 201 million [1] - Following the acquisition, JPMorgan's total holdings in Lattice Technology rose to approximately 8.6152 million shares, with a new ownership percentage of 13.07% [1]

Group 1: IPO Market Activity - The Hong Kong IPO market remained active from February 9 to 15, with 18 companies submitting listing applications, 1 company passing the hearing, and 2 companies completing their public offerings [1] - Six new stocks were listed during this period, with several A-share listed companies initiating "A+H" dual listing processes [1] Group 2: Notable Listings - Haizhi Technology Group (02706.HK) was listed on February 13, with an initial price of HKD 27.06 per share, closing at HKD 92.60 on its first day, marking a 242.20% increase and a market capitalization exceeding HKD 37 billion [4] - The company received a subscription rate of 5065.06 times during the public offering phase and raised approximately HKD 655.4 million [4] Group 3: Company Submissions - Siyuan Electric (002028.SZ) submitted its listing application to the Hong Kong Stock Exchange on February 11, with CITIC Securities as the sole sponsor. The company ranks third among private enterprises in China's power distribution and control equipment market, holding a market share of 3.5% [3] - Other companies that submitted applications include Jingxin Pharmaceutical (002020.SZ) and Xinlitai (002294.SZ), both focusing on central nervous and cardiovascular diseases [3] Group 4: Market Trends - The IPO submissions included companies from various sectors, such as VDL Technology in consumer electronics, Helian Group in bulk commodity services, and Hai Rou Innovation in warehouse robotics [3] - In the biopharmaceutical sector, multiple companies, including Vimo Bio, Yimufeng Bio, Plai Medical, and Noling Bio, also submitted applications [3]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Group 1 - The Hong Kong IPO market is experiencing a "dual increase" in both quality and quantity, with a strong preference for globally competitive "Chinese champion" companies [1][2] - The trend of "China for global" is gaining recognition among international investors, leading to a diverse range of companies seeking to list in Hong Kong for international business expansion [2][3] - The active IPO market is expected to enhance liquidity, which in turn can positively impact valuations, creating a virtuous "flywheel effect" [1][5] Group 2 - The shift in motivations for companies going public has evolved, with many now viewing listing in Hong Kong as a strategic step for internationalization rather than just a means of raising funds [2][3] - Regulatory support from both the Chinese and Hong Kong authorities has facilitated the listing process for high-quality A-share companies, encouraging them to seek international capital markets [2][5] - The anticipated IPO market in 2026 is expected to remain active, driven by an increase in listings from quality A-share companies and emerging sectors like AI and semiconductors [3][5] Group 3 - International investors are increasingly recognizing the value of Chinese companies, particularly those in manufacturing and high-growth sectors such as semiconductors and AI [6] - The presence of international cornerstone investors in recent IPOs indicates a growing confidence in the Hong Kong market and Chinese companies [5][6] - The Hong Kong market offers significant long-term value for companies, providing efficient capital-raising opportunities and facilitating rapid growth through streamlined refinancing processes [6]

Group 1 - Morgan Stanley increased its stake in Lattice Semiconductor (06809) by 1.13246 million shares at a price of 177.6932 HKD per share, totaling approximately 201 million HKD [1][3] - After the increase, Morgan Stanley's total shareholding in Lattice Semiconductor is approximately 8.6152 million shares, representing a stake of 13.07% [1][3]

证券日报网讯2月13日，澜起科技在互动平台回答投资者提问时表示，DRAM内存模组(如RDIMM和 MRDIMM)属于服务器主内存，与HBM的应用场景不同，分别有相对独立的市场空间，二者都将受益于 AI产业的发展，并非竞争或替代关系。公司经营情况正常。 ...

Group 1 - Morgan Stanley increased its stake in Lattice Semiconductor (06809) by 1.13246 million shares at a price of HKD 177.6932 per share, totaling approximately HKD 201 million [1] - After the increase, Morgan Stanley's total shareholding in Lattice Semiconductor is approximately 8.6152 million shares, representing a stake of 13.07% [1]

智通财经APP获悉，香港联交所最新资料显示，2月10日，摩根大通增持澜起科技(06809)113.246万股， 每股作价177.6932港元，总金额约为2.01亿港元。增持后最新持股数目约为861.52万股，最新持股比例 为13.07%。 ...

Core Insights - The article reports that Zhizhu is planning a secondary listing on the Shanghai STAR Market after completing a $558 million IPO in Hong Kong [1] - Zhizhu's stock price surged 23.4% to 496 HKD (approximately 438.5 CNY) on the day of the report, marking a cumulative increase of about 320% since its listing on January 8 [1] - The company has appointed Guotai Junan and CICC as advisors for its STAR Market listing, aiming to broaden its investor base and leverage the higher valuation premium of A-shares compared to H-shares [1] Company Strategy - Zhizhu is part of a recent trend of Chinese tech companies listing in Hong Kong, alongside competitors like MiniMax and chip design firm Lanke Technology [1] - Unlike most companies that follow a "A first, then H" path, Zhizhu is opting for a "H first, then A" strategy, which may enhance its ability to attract domestic capital [1] - The STAR Market has seen a 9% increase in the STAR 50 Index this year, contrasting with a nearly 3% decline in the Hang Seng Tech Index [1] Market Context - Analyst Chelsey Tam from Morningstar noted that A-shares still hold a valuation premium over H-shares, which could benefit Zhizhu's listing strategy [1] - The company is expected to capitalize on investor interest in its GLM-5 model, which ranks first in the open-source model rankings by Artificial Analysis [1]

（原标题：澜起科技(06809)因超额配股权获悉数行使而发行988.35万股） 智通财经APP讯，澜起科技(06809)发布公告，于2026年2月13日因超额配股权获悉数行使而发行及配发 988.35万股H股。 fund ...